MÖLNDAL, SWEDEN
Cellectricon is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 7893748, protecting the company’s innovative technology for creating high-density arrays of compartmentalized cell cultures in multi-well plate formats.
The patent covers a novel multi-well plate design that enables the creation of large numbers of compartmentalized cell culture (CCC) systems within a standardized high-throughput format. The technology allows researchers to physically separate different cellular compartments while maintaining functional connectivity through precisely engineered microstructures, making it possible to study complex biological processes in a scalable and reproducible manner.
Originally developed to address limitations in traditional cell culture platforms, the invention facilitates the generation of advanced in vitro models that more closely mimic physiological cellular interactions. The platform is particularly valuable for neuroscience applications, including studies of neurite outgrowth, axonal transport, neuronal connectivity, and mechanisms underlying neurodegenerative diseases. Its compatibility with high-capacity screening workflows enables researchers to combine physiological relevance with experimental scalability.
“This patent grant represents an important milestone for Cellectricon and validates the innovative work our team has invested in developing next-generation assay platforms,” says Mathias Karlsson, CEO at Cellectricon. “The technology enables our researchers to implement sophisticated CCC models in a format suitable for high-throughput applications, helping to bridge the gap between biological relevance and screening capacity.”
The Japanese patent strengthens Cellectricon’s intellectual property portfolio in a strategically important market. A corresponding patent application covering the same invention is currently pending before the European Patent Office, supporting the company’s efforts to secure broad international protection for this technology.
The patent grant further strengthens Cellectricon’s position as a leading provider of advanced in vitro neurobiology solutions and supports the company’s mission to accelerate the discovery of new therapies for diseases affecting the nervous system.